Cancer Immunology, ImmunotherapyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

627 records returned

Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccinationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article focuses on how the frequency, phenotype, and functions of dendritic cells are altered during the lymphopenic and recovery phases post-induction of lymphodepletion, and how they affect the anti-tumor responses of adoptively transferred T cells. Content Type Journal ArticleCategory ReviewDOI 10.1007/s00262-009-0792-6Authors Mohamed Labib Salem, Medical University of South Carolina Surgery Department Charleston SC 29425 USADavid J. Cole, Medical University of South Carolina Surgery Department Charleston SC 29425 USA Journal Cancer Immunology, ImmunotherapyOnline ISSN 1432-0851Print ISSN 0340-7004 (S...
Source: Cancer Immunology, Immunotherapy - November 18, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

A persistent virus vector confers superior anti-tumor immunity, compared with a non-persistent vectorEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this report, we show that a persistent gammaherpesvirus vector provides superior protection against melanoma, relative to a non-persistent mutant of the same virus. These data suggest that vaccine vectors derived from persistent viruses may perform better than those from acute viruses at mediating anti-tumor protection. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00262-009-0790-8Authors Weijun Zhang, Dartmouth Medical School Department of Microbiology and Immunology 1 Medical Center Drive Lebanon NH 03756 USATong Zhang, Dartmouth Medical School Department of Microbiology and Immunology 1 Med...
Source: Cancer Immunology, Immunotherapy - November 18, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

TNF-alpha-treated DC exacerbates disease in a murine tumor metastasis modelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Due to the pivotal role that dendritic cells (DC) play in eliciting functional anti-tumor T cell responses, immunotherapeutic approaches utilizing DC-based vaccines have readily been exploited. It has been argued that, in the setting of immunotherapy, mature DC will be more efficient at T cell priming and, therefore, required for effective vaccination. As TNF-alpha is commonly used as a DC maturation factor, we have examined the efficacy of treatment with DC matured with TNF-alpha (DC-TNF) in a murine model of melanoma. We have now shown that treatment with DC-TNF leads to an increase in the number ...
Source: Cancer Immunology, Immunotherapy - November 18, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Epstein–Barr virus (EBV)-related malignancies such as post-transplant lymphoproliferative disease (PTLD) are severe complications after allogeneic stem cell transplantation and solid-organ transplantation. In immunosuppressed transplant recipients, the activity of EBV-specific CTLs are often decreased or absent which leads to an increased risk of developing PTLD. If primary treatment modalities of PTLD fail, the most efficient way of treating the malignancy is adopting EBV-specific CTLs from the donor or, more recently, third-party donors. However, both are time consuming and expensive and often i...
Source: Cancer Immunology, Immunotherapy - November 11, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, itCD8+ T/itFOXP3+ cell ratio is a predictive marker for both disease-free survival time and overall survival time in patients with colorectal cancer. Importantly, itCD8+ T/itFOXP3+ cell ratio may be an independent prognostic factor. And, tumor-producing TGF-β may contribute to the increased number of itFOXP3+ cells. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00262-009-0781-9Authors Hiroyuki Suzuki, Kyushu University Department of Cancer Therapy and Research, Graduate School of Medical Sciences 3-1-1 Maidashi, Higashi-Ku Fukuoka 812-8582 JapanNobuhito Chikazawa, Kyushu Universit...
Source: Cancer Immunology, Immunotherapy - November 11, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We describe herein a novel HLA-A*0201-restricted epitope, encompassing amino acids 828–836 (residues QIAKGMSYL), which is naturally presented by various HER-2/neu + tumor cell lines. HER-2/neu(828-836), [HER-2(9828)], possesses two anchor residues and stabilized HLA-A*0201 on T2 cells in a concentration-dependent Class I binding assay. This peptide was stable for 3.5 h in an off-kinetic assay. HER-2(9828) was found to be immunogenic in HLA-A*0201 transgenic (HHD) mice inducing peptide-specific and functionally potent CTL and long-lasting anti-tumor immunity. Most important, using HLA-A*0201 pentamer analysis we ...
Source: Cancer Immunology, Immunotherapy - November 11, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of this project was to investigate whether a serum-free medium exists that performs as well as lab-own serum/media combinations with regard to antigen-specific responses and background reactivity in Elispot. In this way, a straightforward solution could be provided to address the serum challenge. Eleven laboratories tested peripheral blood mononuclear cells (PBMC) from four donors for their reactivity against two peptide pools, following their own Standard Operating Procedure (SOP). Each laboratory performed five simultaneous experiments with the same SOP, the only difference between the experiments was ...
Source: Cancer Immunology, Immunotherapy - November 5, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p = 0.0061) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The study reported here employed the identical vaccine in mCRPC to investigate the influence of GM-CSF with vaccine, and the influence of immunologic and prognostic factors on median OS. Thirty-two patients were vaccinated once with recombinant vaccinia containing the transgenes for prostate-specific antigen (PSA) and three costimulatory molecules. Patients...
Source: Cancer Immunology, Immunotherapy - November 4, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Response to Dr Derhovanessian “Impact of cytomegalovirus infection on immune signatures in cancer patients”Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Letter to the editorDOI 10.1007/s00262-009-0787-3Authors Yen-Ta Lu, Mackay Memorial Hospital Medical Research Department No. 45, Minsheng Rd., Tamsui Town Taipei 25160 TaiwanI-Hsuan Chen, Mackay Memorial Hospital Medical Research Department No. 45, Minsheng Rd., Tamsui Town Taipei 25160 Taiwan Journal Cancer Immunology, ImmunotherapyOnline ISSN 1432-0851Print ISSN 0340-7004 (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - November 3, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2′-deoxycytidineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Tumor-recruited CD11b myeloid cells, including myeloid-derived suppressor cells, play a significant role in tumor progression, as these cells are involved in tumor-induced immune suppression and tumor neovasculogenesis. On the other hand, the tumor-infiltrated CD11b myeloid cells could potentially be a source of immunostimulatory antigen-presenting cells (APCs), since most of these cells represent common precursors of both dendritic cells and macrophages. Here, we investigated the possibility of generating mature APCs from tumor-infiltrated CD11b myeloid cells. We demonstrate that in vitro exposure ...
Source: Cancer Immunology, Immunotherapy - October 31, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant settingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract About 30% of renal cell carcinomas (RCC) will develop recurrence after surgery. Despite evidence for a significantly improved survival by autologous tumour cell vaccination therapy, the procedure has not become standard. Between August 1993 and December 1996, 1,267 RCC patients undergoing radical nephrectomy in 84 German hospitals were subsequently treated by autologous tumour cell vaccination therapy. The study group comprised 692 patients with complete follow-up (stages pT2-3, pNx-2, M0 based on the TNM classification, 4th edition). Subsequent propensity-score matching according to 7 defined crite...
Source: Cancer Immunology, Immunotherapy - October 29, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Cancer testis antigens and melanoma stem cells: new promises for therapeutic interventionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Letter to the editorDOI 10.1007/s00262-009-0785-5Authors Luca Sigalotti, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico Cancer Bioimmunotherapy Unit, Department of Medical Oncology Via F. Gallini 2 33081 Aviano ItalyAlessia Covre, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico Cancer Bioimmunotherapy Unit, Department of Medical Oncology Via F. Gallini 2 33081 Aviano ItalyHugues J. M. Nicolay, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico Cancer Bioimmunotherapy Unit,...
Source: Cancer Immunology, Immunotherapy - October 28, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Nuclear factor kappaB-activated monocytes contribute to pancreatic cancer progression through the production of ShhEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this report, we present for the first time that inflammation-stimulated monocytes produce Shh through activation of the NF-κB signaling pathway, and that the Shh produced promotes the proliferation of pancreatic cancer cells in a paracrine manner through Hh signaling. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00262-009-0783-7Authors Akio Yamasaki, Kyushu University Department of Cancer Therapy and Research, Graduate School of Medical Sciences 3-1-1 Maidashi, Higashi-ku Fukuoka 812-8582 JapanChizu Kameda, Kyushu University Department of Cancer Therapy and Research, Graduate School of Medic...
Source: Cancer Immunology, Immunotherapy - October 28, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Advances in cellular therapy: 5th International Symposium on the clinical use of cellular products, 19 and 20 March 2009, Nürnberg, GermanyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Meeting ReportDOI 10.1007/s00262-009-0779-3Authors Evelyn Ullrich, University of Erlangen-Nürnberg Department of Internal Medicine 5, Hematology/Oncology Krankenhausstrasse 12 91054 Erlangen GermanyJacobus Bosch, University of Erlangen-Nürnberg Department of Internal Medicine 5, Hematology/Oncology Krankenhausstrasse 12 91054 Erlangen GermanyMichael Aigner, University of Erlangen-Nürnberg Department of Internal Medicine 5, Hematology/Oncology Krankenhausstrasse 12 91054 Erlangen GermanySimon Völkl, University of Erlangen-Nürnberg Department of Internal Medicine 5, Hematology/On...
Source: Cancer Immunology, Immunotherapy - October 28, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract FoxP3 + CD4 + regulatory T cells (Tregs) are important mediators of peripheral immune tolerance, acting via multiple mechanisms to suppress cellular immunity including antitumor responses. Although therapeutic strategies have been proposed to deplete Tregs in patients with breast cancer and other malignancies, dynamic changes in the Treg compartment as a function of stage and treatment of breast cancer remain poorly understood. Here, we evaluated peripheral blood CD4+ T cells and FoxP3+ CD4+ T cells from 45 patients with early or late stage breast cancer and compared percentages, absolute counts,...
Source: Cancer Immunology, Immunotherapy - October 23, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Multimer technologies for detection and adoptive transfer of antigen-specific T cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Identification and purification of antigen-specific T cells without altering their functional status are of high scientific and clinical interest. Staining with major histocompatibility complex (MHC)-peptide multimers constitutes a very powerful method to study antigen-specific T-cell subpopulations, allowing their direct visualization and quantification. MHC-peptide multimers, such as dimers, tetramers, pentamers, streptamers, dextramers and octamers have been used to evaluate the frequency of CD8+ T cells, specific for tumor/leukemia-associated antigens as well as for viral antigens, e.g., CMVpp65...
Source: Cancer Immunology, Immunotherapy - October 21, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Type I interferons inhibit the generation of tumor-associated macrophagesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Tumor-associated macrophages (TAM) are very abundant in tumors and are thought to play a major role in promoting tumor growth. The generation of TAM is positively regulated by several cytokines, including colony stimulating factor-1 (CSF-1) and monocyte chemoattractant protein-1 (CCL2). However, endogenous factors that suppress the generation of TAM within tumors have not been previously identified. An earlier study showed that endogenously produced type I interferons (IFN) suppressed tumor growth via their effects on hematopoietic cells rather than through direct effects on tumor cells. Therefore, ...
Source: Cancer Immunology, Immunotherapy - October 13, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine releaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract The aims of this study are to examine the effect of sphingosine 1-phosphate (S1P) on IL-2-activated natural killer (NK) cell lysis of K562 tumor cells and immature dendritic cells (iDCs), and to investigate the mechanisms involved in S1P activity. Our results show that S1P protected K562 cells or iDCs from NK cell lysis, which was reversed by FTY720 and SEW2871, the antagonists of S1P1. S1P did not modulate the expression of NKG2D, NKp30, NKp44 or CD158 on the surface of NK cells, and neither affected the expression of CD80, CD83, or CD86 on the surface of DCs. In contrast, it increased the expressi...
Source: Cancer Immunology, Immunotherapy - October 13, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Erratum to: Amyloid precursor-like protein 2 association with HLA class I moleculesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory ErratumDOI 10.1007/s00262-009-0777-5Authors Amit Tuli, University of Nebraska Medical Center Eppley Institute for Research in Cancer and Allied Diseases Omaha NE USAMahak Sharma, University of Nebraska Medical Center Department of Biochemistry and Molecular Biology Omaha NE USAXiaojian Wang, University of Nebraska Medical Center Eppley Institute for Research in Cancer and Allied Diseases Omaha NE USALaura C. Simone, University of Nebraska Medical Center Eppley Institute for Research in Cancer and Allied Diseases Omaha NE USAHaley L. Capek, University of Nebraska Medical Center Epple...
Source: Cancer Immunology, Immunotherapy - October 13, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Defects in HLA class I antigen processing machinery (APM) component expression often have a negative impact on the clinical course of tumors and on the response to T cell-based immunotherapy. Since only scant information is available about the frequency and clinical significance of HLA class I APM component abnormalities in prostate cancer, the APM component expression pattern was analyzed in 59 primary prostate carcinoma, adjacent normal tissues, as well as in prostate carcinoma cell lines. The IFN-γ inducible proteasome subunits LMP2 and LMP7, TAP1, TAP2, calnexin, calreticulin, ERp57, and tapasi...
Source: Cancer Immunology, Immunotherapy - October 10, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma modelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract The immunosuppressive environment of malignant gliomas is likely to suppress the anti-tumor activity of infiltrating microglial cells and lymphocytes. Macrophages and microglial cells may be activated by oligonucleotides containing unmethylated CpG-motifs, although their value in cancer immunotherapy has remained controversial. Following injection of CpG-containing oligonucleotides (ODN) into normal rat brain, we observed a local inflammatory response with CD8+ T cell infiltration, upregulation of MHC 2, and ED1 expression proving the immunogenic capacity of the CpG-ODN used. This was not observed w...
Source: Cancer Immunology, Immunotherapy - October 1, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune responseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Lung cancer is the leading cause of cancer-related mortality in the world, resulting in over a million deaths each year. Non-small cell lung cancers (NSCLCs) are characterized by a poor immunogenic response, which may be the result of immunosuppressive factors such as prostaglandin E2 (PGE2) present in the tumor environment. The effect of PGE2 in the suppression of anti-tumor immunity and its promotion of tumor survival has been established for over three decades, but with limited mechanistic understanding. We have previously reported that PGE2 activates hematopoietic progenitor kinase 1 (HPK1), a he...
Source: Cancer Immunology, Immunotherapy - September 29, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor propertiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract The identification and validation of new cancer-specific T cell epitopes continues to be a major area of research interest. Nevertheless, challenges remain to develop strategies that can easily discover and validate epitopes expressed in primary cancer cells. Regarded as targets for T cells, peptides presented in the context of the major histocompatibility complex (MHC) are recognized by monoclonal antibodies (mAbs). These mAbs are of special importance as they lend themselves to the detection of epitopes expressed in primary tumor cells. Here, we use an approach that has been successfully utilized ...
Source: Cancer Immunology, Immunotherapy - September 24, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

CD4+CD45RA+CXCR4+ lymphocytes are inversely associated with progression in stages I–III melanoma patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract The chemokine receptor CXCR4 was described as an independent predictor of poor prognosis in primary human melanoma. To investigate on a possible role of CXCR4 expression on peripheral blood lymphocytes (PBL) subsets, 195 patients with melanoma were evaluated for correlations between PBL subsets CXCR4 expressing and clinicopathological and prognostic features. One hundred ninety-five patients with stages I–III melanoma were enrolled in this study. Lymphocytes subsets were assayed by the direct fluorescence method for whole blood and staining with fluorochrome-conjugated monoclonal antibodies. Corre...
Source: Cancer Immunology, Immunotherapy - September 24, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract This is the first phase III randomised trial to evaluate maintenance immunotherapy in metastatic renal cell cancer (mRCC). Patients were randomised to receive treatment with a 4-week cycle of subcutaneous low doses IL-2 + IFN in months 1, 3 and 5, and then every 3 months until the first documented disease progression (arm A, suspension), or the same regimen, with chronic maintenance of immunotherapy, regardless of tumour response, until death or intolerable toxicity (arm B, maintenance). The primary endpoint was overall survival (OS); secondary endpoints were time from first progressi...
Source: Cancer Immunology, Immunotherapy - September 24, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Meeting ReportDOI 10.1007/s00262-009-0770-zAuthors Mustafa Diken, Johannes Gutenberg-University III. Medical Department of University Medical Center Mainz GermanyMelanie Widenmeyer, University of Tübingen Department of Immunology Tübingen GermanyCécile Gouttefangeas, University of Tübingen Department of Immunology Tübingen GermanyMarij J. P. Welters, Leiden University Medical Center Department of Immunohematology and Blood Transfusion Leiden The NetherlandsCedrik M. Britten, Johannes Gutenberg-University III. Medical Department of University Medical Center Mainz Germany ...
Source: Cancer Immunology, Immunotherapy - September 21, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Therapeutic vaccination holds great potential as complementary treatment for non-Hodgkin’s lymphoma. Here, we report that a therapeutic whole cell vaccine formulated with IL-2 adsorbed onto aluminum hydroxide as cytokine-depot formulation elicits potent antitumor immunity and induces delayed tumor growth, control of tumor dissemination and longer survival in mice challenged with A20-lymphoma. Therapeutic vaccination induced higher numbers of tumor’s infiltrating lymphocytes (CD4+ and CD8+ T cells and NK cells), and the production of IFN-γ and IL-4 by intratumoral CD4+ T cells. Further, strong tu...
Source: Cancer Immunology, Immunotherapy - September 18, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Prognostic value of CD208-positive cell infiltration in gastric cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion We showed that intratumoral CD208-positive cells, as mature DCs, had an inverse correlation to patients’ postoperative outcome in gastric cancer, unlike a conventional DC marker. Evaluation of CD208-positive cell infiltration with S100-positive cell infiltration in gastric cancer is useful to predict antitumor immunological conditions in gastric cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00262-009-0758-8Authors Sumiya Ishigami, Kagoshima University School of Medicine Digestive Surgery Surgical Oncology 8-35-1 Sakuragaoka Kagoshima 890-8520 JapanShinichi Ueno...
Source: Cancer Immunology, Immunotherapy - September 17, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Impact of Cytomegalovirus infection on immune signatures in cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Letter to the editorDOI 10.1007/s00262-009-0767-7Authors Evelyna Derhovanessian, University of Tübingen Medical School Center for Medical Research Waldhörnlestr. 22 72072 Tübingen Germany Journal Cancer Immunology, ImmunotherapyOnline ISSN 1432-0851Print ISSN 0340-7004 (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - September 17, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Malignant histiocytosis (MH) is an aggressive cancer derived from myeloid lineage cells in both dogs and humans. In dogs, the tumor is characterized by the rapid development of metastatic tumors in multiple sites, including especially the lungs and lymph nodes. Humans develop an analogous disease known as Langerhans cell histiocytosis, which primarily affects children and young adults. Because these tumors are often resistant to conventional chemotherapy, there is a need for newer therapeutic approaches. Systemic administration of liposomal clodronate (LC) has been shown to effectively deplete phago...
Source: Cancer Immunology, Immunotherapy - September 17, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 contextEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract We characterized a new melanoma antigen derived from one of the multiple open reading frames (ORFs) of the meloe transcript. The meloe gene is overexpressed in melanomas as compared to other cancer cell lines and normal tissues. The corresponding transcript is rather unusual, in that it does not contain a long unique ORF but multiple short ORFs. We recently characterized a tumor epitope derived from a polypeptide (MELOE-1) encoded by the ORF1230–1370 and involved in relapse prevention of melanoma patients treated with autologous tumor infiltrating lymphocytes (TIL). Here we show that the ORF285–4...
Source: Cancer Immunology, Immunotherapy - September 17, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Natural killer cell is a major producer of interferon γ that is critical for the IL-12-induced anti-tumor effect in miceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, NK cells are predominant producers of IFNγ that is critical for IL-12 anti-tumor therapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00262-009-0764-xAuthors Akio Uemura, Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology 2-2 Yamada-oka Suita, Osaka 565-0871 JapanTetsuo Takehara, Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology 2-2 Yamada-oka Suita, Osaka 565-0871 JapanTakuya Miyagi, Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology 2-2 Yamada-oka Suita, Osak...
Source: Cancer Immunology, Immunotherapy - September 16, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions In this study, we demonstrate that concurrent administration of two vaccines targeting the same antigen induces a more diverse T-cell population that leads to enhanced antitumor efficacy. These studies provide the rationale for future clinical studies investigating concurrent administration of vaccine platforms targeting a single antigen to enhance the antigen-specific immune response. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00262-009-0759-7Authors Amanda L. Boehm, National Institutes of Health Laboratory of Tumor Immunology and Biology, Center for Cancer Researc...
Source: Cancer Immunology, Immunotherapy - September 16, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Most APM components were downregulated in UC. High-stage UC had lower scores for immunoproteasome components compared to low-stage UC. Delta and calreticulin protein expression was associated with survival in UC and in all types of BC, respectively. These findings suggest that APM defects play a role in the clinical course of BC and should be considered in developing immunotherapeutic approaches for its control. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00262-009-0765-9Authors Helen P. Cathro, University of Virginia Health System Department of Pathology PO Box 8002...
Source: Cancer Immunology, Immunotherapy - September 16, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Intratumoral DNA electroporation induces anti-tumor immunity and tumor regressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract In situ expression of a foreign antigen and an immune-modulating cytokine by intratumoral DNA electroporation was tested as a cancer therapy regimen. Transgene expression in the tumors was sustained for 2–3 weeks after intratumoral electroporation with mammalian expression plasmid containing firefly luciferase cDNA. Electroporation with cDNA encoding tetanus toxin fragment C (TetC) induced tetanus toxin-binding antibody, demonstrating immune recognition of the transgene product. Intratumoral electroporation with TetC and IL-12 cDNA after mice were treated with CD25 mAb to remove regulatory T ...
Source: Cancer Immunology, Immunotherapy - September 16, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory ReviewDOI 10.1007/s00262-009-0757-9Authors Rebecca Liu, The Preston Robert Tisch Brain Tumor Center at Duke Durham NC USADuane A. Mitchell, The Preston Robert Tisch Brain Tumor Center at Duke Durham NC USA Journal Cancer Immunology, ImmunotherapyOnline ISSN 1432-0851Print ISSN 0340-7004 (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - September 16, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we addressed the immunogenicity of apoptotic ovarian cancer cells induced by paclitaxel and carboplatin, the immunologic aspects in ovarian cancer patients under chemotherapy, and the CTL response when CD8+ T cells were stimulated with tumor antigen in the “window” period. The immunogenicity of apoptotic ovarian cancer cells was detected first. Then, blood samples from each ovarian cancer patient were obtained before (S0) and at days 5–7 (S1), days 12–14 (S2) and days 25–28 (S3) after chemotherapy. The proportions of immunocyte subsets and the function of NK cells were studied. We found that apo...
Source: Cancer Immunology, Immunotherapy - September 3, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we show that allogeneic effector cells (from a healthy donor or AML patients) when stimulated with IL-2/CD80 modified AML blasts were able to induce the lysis of unmodified AML blasts. Effector cells stimulated with IL-2/CD80AML blasts had higher lytic activity than cells stimulated with AML cells expressing CD80 or IL-2 alone. Similarly, AML patient PBMCs primed with autologous IL-2/CD80 AML cells had a higher frequency of IFN-γ secreting cells and show cytotoxicity against autologous, unmodified blasts. Crucially, the response appears to be leukaemia specific, since stimulated patient PBMCs show high...
Source: Cancer Immunology, Immunotherapy - August 27, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responsesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Clinical studies over the past several years have reported that metastasis-free survival times in humans and dogs with osteosarcoma are significantly increased in patients that develop chronic bacterial osteomyelitis at their surgical site. However, the immunological mechanism by which osteomyelitis may suppress tumor growth has not been investigated. Therefore, we used a mouse model of osteomyelitis to assess the effects of bone infection on innate immunity and tumor growth. A chronic Staphylococcal osteomyelitis model was established in C3H mice and the effects of infection on tumor growth of syng...
Source: Cancer Immunology, Immunotherapy - August 22, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we identified patients with Yo antibodies who also had antibodies to an uncharacterized protein called coiled-coil domain-containing protein 104 (CCDC104). We found a significant association between CCDC104 and Yo antibodies (4 of 38, 10.5%), but not other onconeural antibodies (0 of 158) (P = 0.007, Fisher’s exact test). The prevalence of CCDC104 antibodies was approximately similar in patients with cancer (8 of 756, 1.1%) and in healthy blood donors (2 of 300, 0.7%). CCDC104 antibodies were not associated with PNS, as this was found in only two of the ten CCDC104-positive patients. The CCDC...
Source: Cancer Immunology, Immunotherapy - August 19, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, a mouse anti-human OPN antibody (1A12) was humanized by complementarity-determining region grafting method based on computer-assisted molecular modeling. A humanized version of 1A12, denoted as hu1A12, was shown to possess affinity comparable to that of its parental antibody. The ability of hu1A12 to inhibit cell migration, adhesion, invasion and colony formation was assessed in a highly metastatic human breast cancer cell line MDA-MB-435S. The results indicated that hu1A12 was effective in inhibiting the cell adhesion, migration, invasion and colony formation of MDA-MB-435S cells in vitro. hu1A12 also ...
Source: Cancer Immunology, Immunotherapy - August 19, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study provides important evidence for IP IL-2 in platinum-resistant ovarian cancer and identifies several immune correlates of survival. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00262-009-0750-3Authors Anda M. Vlad, University of Pittsburgh School of Medicine Department of Obstetrics, Gynecology, and Reproductive Sciences 300 Halket Str Pittsburgh PA 15213 USARaluca A. Budiu, University of Pittsburgh School of Medicine Department of Obstetrics, Gynecology, and Reproductive Sciences 300 Halket Str Pittsburgh PA 15213 USADiana E. Lenzner, University of Pittsburgh Cancer Institute 201 North...
Source: Cancer Immunology, Immunotherapy - August 19, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Although immunodeficiency is usually considered a prerequisite of oncogenesis, a detailed immune profile in cancer has not yet been described. Without such profiling, it is not surprising that there is a vast discrepancy in the responses of cancer patients to immunotherapy. Our results show that the integrity of the immune system deteriorates with cancer progression by displaying a trend toward decreasing levels of functional T cells, including CD4, naïve, and central memory T cells, and an expansion of hyporesponsive populations such as CD28− and CMV-specific T cells. One hundred and one patient...
Source: Cancer Immunology, Immunotherapy - August 14, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract The reduction or loss of MHC-I antigen surface expression in human and murine tumor cells is partly attributable to the dysregulation of various components of the MHC-I antigen-processing machinery. Accumulating evidence suggests that autophagy, besides its vital role in maintaining the cellular homeostasis, plays an important role in MHC-II surface expression. Here, we report that autophagy is a negative regulator of MHC-I antigen expression in B16 melanoma cells; however, in the presence of IFN-γ, it is converted to a positive regulator. We show that autophagy not only participates in the degrada...
Source: Cancer Immunology, Immunotherapy - August 12, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract The appearance of vitiligo and spontaneous regression of the primary lesion in melanoma patients illustrate a relationship between tumor immunity and autoimmunity. T lymphocytes play a major role both in tumor immunity and autoimmunity. CD28, Cytotoxic T lymphocyte antigen 4 (CTLA4) and inducible costimulator (ICOS) molecules are important secondary signal molecules in the T lymphocyte activation. Single nucleotide polymorphisms (SNPs) in the CD28/CTLA4/ICOS gene region were reported to be associated with several autoimmune diseases including, type-1 diabetes, SLE, autoimmune thyroid diseases and ce...
Source: Cancer Immunology, Immunotherapy - August 11, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Tumors induce the formation of suppressor endothelial cells in vivoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Patients with solid tumors have defects in immune effector cells, which have been associated with a poorer prognosis. Previous studies by our laboratory have shown that exposure to Lewis lung carcinoma (LLC)-secreted products induces the formation of suppressor endothelial cells in vitro. The current studies examined if tumors could induce the formation of suppressor endothelial cells in vivo. Endothelial cells were immunomagnetically isolated from the lungs of tumor-bearing mice or normal controls and examined for their ability to modulate NK cell, T-cell and macrophage functions. Compared to norma...
Source: Cancer Immunology, Immunotherapy - August 9, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

The second cellular therapy of cancer symposium, 27–29 March 2009, Milan, ItalyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Meeting ReportDOI 10.1007/s00262-009-0748-xAuthors John S. Bridgeman, The University of Manchester Cellular Therapy Group, Department of Medical Oncology Manchester UKDavid E. Gilham, The University of Manchester Cellular Therapy Group, Department of Medical Oncology Manchester UKRobert E. Hawkins, The University of Manchester Cellular Therapy Group, Department of Medical Oncology Manchester UKEleanor J. Cheadle, The University of Manchester Cellular Therapy Group, Department of Medical Oncology Manchester UK Journal Cancer Immunology, ImmunotherapyOnline ISSN 1432-0851Print ...
Source: Cancer Immunology, Immunotherapy - August 9, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignanciesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract A human anti-CD19 antibody was expressed in fucosyltransferase-deficient CHO cells to generate nonfucosylated MDX-1342. Binding of MDX-1342 to human CD19-expressing cells was similar to its fucosylated parental antibody. However, MDX-1342 exhibited increased affinity for FcγRIIIa-Phe158 and FcγRIIIa-Val158 receptors as well as enhanced effector cell function, as demonstrated by increased potency and efficacy in antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis assays. MDX-1342 showed dose-dependent improvement in survival using a murine B-cell lymphoma model in which Ramos cells wer...
Source: Cancer Immunology, Immunotherapy - August 5, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Loci controlling lymphocyte production of interferon γ after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibilityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Low infiltration of lymphocytes into cancers is associated with poor prognosis, but the reasons why some patients exhibit a low and others a high infiltration of tumors are unknown. Previously we mapped four loci (Lynf1–Lynf4) controlling lymphocyte infiltration of mouse lung tumors. These loci do not encode any of the molecules that are involved in traffic of lymphocytes. Here we report a genetic relationship between these loci and the control of production of IFNγ in allogeneic mixed lymphocyte cultures (MLC). We found that IFNγ production by lymphocytes of O20/A mice is lower than by lymphocy...
Source: Cancer Immunology, Immunotherapy - August 4, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals

Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract In the present study, either modified IFL regimen (modified irinotecan, fluorouracil and leucovorin, mIFL) alone or in combination with bevacizumab was used to treat patients with metastatic colorectal cancer (CRC). Treatment efficacy was assessed using coupled tomography imaging diagnosis. The toxicity accompany with treatment was evaluated, as well as T cell receptor (TCR) repertoire before and several cycles after therapy was dynamically monitored by analyzing the complementarity-determining region 3 (CDR3) length distribution within CD4+ and CD8+ T cell subsets. The degrees of normalization of t...
Source: Cancer Immunology, Immunotherapy - August 3, 2009 Category: Cancer & Oncology Tags: Cancer Immunology, Immunotherapy Source Type: journals